BioDelivery Sciences International, Inc. (NASDAQ:BDSI) saw a large growth in short interest in November. As of November 30th, there was short interest totalling 1,433,007 shares, a growth of 32.5% from the November 15th total of 1,081,713 shares. Based on an average daily volume of 561,756 shares, the days-to-cover ratio is presently 2.6 days. Currently, 2.8% of the shares of the company are short sold.
A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of BioDelivery Sciences International in a report on Sunday, August 20th. HC Wainwright set a $5.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a report on Friday, October 13th. ValuEngine lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Roth Capital set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Thursday, October 12th. Finally, Piper Jaffray Companies set a $4.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Sunday, October 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $4.29.
Shares of BioDelivery Sciences International (BDSI) opened at $2.70 on Monday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.07 and a current ratio of 1.28. BioDelivery Sciences International has a 52 week low of $1.55 and a 52 week high of $3.60.
In other BioDelivery Sciences International news, insider Mark A. Sirgo sold 201,373 shares of BioDelivery Sciences International stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $2.84, for a total value of $571,899.32. Following the sale, the insider now owns 1,509,262 shares of the company’s stock, valued at approximately $4,286,304.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Mark A. Sirgo sold 24,516 shares of BioDelivery Sciences International stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $2.75, for a total value of $67,419.00. Following the completion of the sale, the chief executive officer now directly owns 1,509,262 shares in the company, valued at approximately $4,150,470.50. The disclosure for this sale can be found here. Insiders sold a total of 291,294 shares of company stock worth $819,182 in the last ninety days. 9.00% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the company. Advisor Group Inc. boosted its stake in shares of BioDelivery Sciences International by 42.1% during the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after acquiring an additional 13,341 shares in the last quarter. Valley National Advisers Inc. boosted its stake in shares of BioDelivery Sciences International by 59.0% during the 2nd quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock worth $106,000 after acquiring an additional 14,000 shares in the last quarter. Stonepine Capital Management LLC boosted its stake in shares of BioDelivery Sciences International by 22.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock worth $9,737,000 after acquiring an additional 632,853 shares in the last quarter. GSA Capital Partners LLP lifted its stake in BioDelivery Sciences International by 10.1% in the 2nd quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock valued at $1,369,000 after buying an additional 44,700 shares in the last quarter. Finally, EAM Investors LLC purchased a new stake in BioDelivery Sciences International in the 2nd quarter valued at approximately $1,348,000. 44.18% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/18/biodelivery-sciences-international-inc-bdsi-short-interest-up-32-5-in-november.html.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
What are top analysts saying about BioDelivery Sciences International? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioDelivery Sciences International and related companies.